Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 29, 2007

Gentris Divests Diagnostics Business

  • Gentris has sold the assets of its diagnostic business arm, Gentris Diagnostics, forming a new company, ParagonDx. The stand-alone company will focus on developing molecular diagnostic products for laboratories.

    “Molecular diagnostics is an emerging market,” Sorge said. “Small, nimble companies such as ParagonDx will be able to adapt to rapidly changing conditions and bring tests to market that will actually help patients.”

    Among the key assets ParagonDx gained are the first six FDA-cleared human genomic reference controls and 46 other reference control products currently being sold to laboratories and diagnostic product developers.

    The company also purchased a new in vitro diagnostic test to determine a safe starting dose of warfarin. This is of particular importance, as on August 16, the FDA updated warfarin’s label to include genetic testing information.

    Joe Sorge, founder and former CEO of Stratagene, has assumed a controlling interest in ParagonDx. Gentris will retain a minority stake in the new company.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »